Saudi Central Bank Has $2.93 Million Position in IDEXX Laboratories, Inc. $IDXX

Saudi Central Bank lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 88.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,560 shares of the company’s stock after acquiring an additional 2,613 shares during the period. Saudi Central Bank’s holdings in IDEXX Laboratories were worth $2,927,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the third quarter worth approximately $26,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories in the second quarter worth approximately $25,000. Elevation Wealth Partners LLC increased its holdings in IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares in the last quarter. Finally, Wormser Freres Gestion lifted its stake in IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the topic of a number of research analyst reports. UBS Group increased their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Barclays decreased their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $535.38 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a fifty day simple moving average of $558.25 and a two-hundred day simple moving average of $569.41. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The firm has a market capitalization of $42.18 billion, a PE ratio of 37.65, a price-to-earnings-growth ratio of 2.86 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.